title: [Two cases of recurrent non-small cell lung cancer successfully treated with S-1 as fifth-line chemotherapy].
abstract: There is at present no defined role for S-1 chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who previously failed chemotherapy. Two cases of multidrug-resistant, NSCLC that were successfully treated with S-1 as fifth-line chemotherapy are reported. A 75-year-old man was diagnosed as having pulmonary adenocarcinoma, cT1N3M0, stage III B. He was treated with S-1 as fifth-line chemotherapy after treatment with cisplatin(CDDP)and vinorelbine(VNR), docetaxel (DOC), gemcitabine (GEM) and VNR, and amrubicin (AMR). After completing two courses, chest computed tomography(CT)showed a partial response( PR)of the recurrent tumors, and the serum carcinoembryonic antigen level decreased. Currently, seven courses have been completed, and this treatment will be continued due to the tumor response of stable disease. A 65-year-old woman was referred for treatment of recurrent pulmonary adenocarcinoma after right upper lobe resection. She was treated with S-1 as fifth-line chemotherapy after treatment with GEM and VNR, carboplatin(CBDCA) and paclitaxel ( PTX), DOC, and gefitinib. After completing five courses, chest CT showed PR of the intrapulmonary metastases. Though grade 3 toxicity-anemia in the first case and an elevated serum amylase level in the second case were observed in both cases, the patients' quality of life was preserved. S-1 could therefore be a treatment option for patients with advanced NSCLC who previously underwent chemotherapy unsuccessfully.
authors.affiliation: Dept. of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences.
authors.forename: Osamu
authors.initials: O
authors.lastname: Takakuwa
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Oguri
authors.forename: Shigeki
authors.initials: S
authors.lastname: Sato
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakao
authors.forename: Chiharu
authors.initials: C
authors.lastname: Ohta
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Iwashima
authors.forename: Mikinori
authors.initials: M
authors.lastname: Miyazaki
authors.forename: Ken
authors.initials: K
authors.lastname: Maeno
authors.forename: Takeo
authors.initials: T
authors.lastname: Kutsuna
authors.forename: Atsushi
authors.initials: A
authors.lastname: Nakamura
authors.forename: Ryuzo
authors.initials: R
authors.lastname: Ueda
mesh_terms: D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004338:Drug Combinations; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D010094:Oxonic Acid / Q000627:therapeutic use*; D011788:Quality of Life; D012008:Recurrence; D016879:Salvage Therapy; D005641:Tegafur / Q000627:therapeutic use*; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid